Abstract
Minichromosome maintenance protein 2 (MCM2), which is a member of MCM family, has been found to be a relevant marker for progression and prognosis in a variety of human cancers. Due to lack of effective therapeutic target in lung squamous cell carcinoma (LUSC) patients, the aim of our study was to screen and identify biomarkers which are associated to clinicopathological characteristics including prognosis in LUSC patients. The expression status of MCM2 in lung cancer was analyzed using the publicly available Gene Expression Omnibus databases (GSE3268 and GSE10245). The mRNA and protein expression of MCM2 in lung cancer tissues and cell lines was detected by quantitative real-time PCR and Western blot, and the association between MCM2 expression and clinicopathological factors was analyzed by immunohistochemistry. The loss-of-function study of MCM2 was conducted in LUSC cell lines. In our study, we found MCM2 expression was increased in LUSC tissues compared with paired adjacent normal lung tissues or lung adenocarcinoma tissues through analyzing microarray data sets (GSE3268 and GSE10245), which confirmed that MCM2 mRNA and protein were overexpressed in LUSC tissues and cell lines. Meanwhile, we analyzed the association betwee...Continue Reading
Citations
Jul 1, 2020·Bioscience Reports·He ZhouTong Zhou
Feb 25, 2020·Analytical Cellular Pathology (Amsterdam)·Si YuYang Chen
May 11, 2019·BMC Cancer·A HendricksC Schrader
Jul 1, 2020·BioMed Research International·Hongxia MaFengsen Li
Sep 14, 2019·International Journal of Molecular Sciences·Hiroki SanadaHiromasa Inoue
Mar 1, 2019·Cancers·Akifumi UchidaHiromasa Inoue
Jan 30, 2020·BMC Genomics·Jiayuan ZhongPei Chen
Jan 29, 2021·Frontiers in Pharmacology·Boyu PanLiren Liu
Jan 16, 2021·Cancer Management and Research·Han XueShuping Liao
May 4, 2021·Frontiers in Genetics·Chen HuangLiren Liu
Jun 4, 2021·OncoTargets and Therapy·Guanghui XieJun Chen
Jun 19, 2021·IScience·Wai-Kok Choong, Ting-Yi Sung
Jul 10, 2021·Frontiers in Molecular Biosciences·Jian ZhouGen Wu
Jul 9, 2021·BMC Cancer·Yaoyao GuZhixiang Wu
Sep 4, 2021·Journal of Oncology·Xinyu LiuChunying Shi
Feb 8, 2022·Diagnostic Pathology·Dorsay SadeghianBehnaz Jahanbin